A Cook County, Illinois jury returned a unanimous defense verdict for Merck & Co., Inc. on April 17, 2026, in a talc-related mesothelioma case that placed medical causation at the center of the dispute. Plaintiff Cole Bassett, 43, alleged that asbestos-contaminated talcum powder products—including powders associated with Dr. Scholl’s and Lotrimin—caused him to develop peritoneal mesothelioma, and he sought roughly $45 million in damages. After a multi-week trial before Judge Gerald Cleary in the Circuit Court of Cook County, the jury deliberated for less than two hours before finding for Merck, underscoring how quickly jurors resolved competing causation narratives.
Allegations and Damages Sought
Bassett’s claims followed a familiar structure in talc litigation, alleging exposure to asbestos through consumer powder use and attributing a rare malignancy to that exposure pathway. Peritoneal mesothelioma is frequently litigated as an asbestos-associated disease, and the plaintiff’s theory depended on linking alleged product contamination to meaningful exposure and, ultimately, to specific causation. As framed at trial, the plaintiff contended that Merck-related talc products were among those that contributed to asbestos exposure sufficient to cause his cancer.
Damages demands reflected the severity of the diagnosis and the asserted impact on life expectancy, quality of life, and financial losses. The approximately $45 million figure signaled an attempt to quantify both economic damages (medical costs and related expenses) and noneconomic damages such as pain and suffering. The allegations also carried the potential for punitive damages at the outset, which often raises the stakes by shifting juror focus toward corporate intent, knowledge, and alleged misconduct rather than medical proof alone.
Merck’s Causation Defense Centered on Genetics
Merck’s trial strategy emphasized specific causation, disputing that any alleged asbestos exposure from talc products caused Bassett’s peritoneal mesothelioma. Instead of limiting the defense to arguments about product composition or exposure levels, Merck advanced an alternative medical explanation: that Bassett carried a genetic mutation associated with elevated mesothelioma risk and that the mutation—not talc-related asbestos exposure—best accounted for the disease. This approach reframed the trial from a product-contamination debate into a competing etiology analysis with a concrete alternative cause.
According to trial summaries and filings, the defense credited expert testimony as a central reason the jury accepted its causation theory. Named defense experts included Dr. Michele Carbone and Dr. Jadee Neff, who addressed the genetic mutation and its implications for mesothelioma risk, as well as Dr. Sahmel and Dr. Barlow. The defense was represented by Sidley Austin, according to court filings. The case illustrates how presenting a cohesive, medically grounded alternative causation narrative can affect juror decision-making even in a category of cases often dominated by disputes over asbestos presence and exposure history.
Mid-Trial Dismissal of Punitive Damages and Trial Dynamics
A significant procedural development occurred mid-trial when Judge Cleary dismissed the plaintiff’s punitive damages claim for lack of evidence. Removing punitive damages narrowed the issues for the jury and reduced the likelihood that deliberations would be influenced by arguments about punishment or deterrence. In practice, this type of ruling can also reshape closing arguments, limiting the plaintiff to compensatory damages theories and requiring a tighter focus on medical causation and proof of liability elements.
The punitive-damages dismissal also highlighted the court’s gatekeeping role in assessing whether the evidentiary record supports submitting heightened remedies to jurors. When punitive claims are pared back, defendants often gain a clearer path to emphasize scientific and medical disputes rather than corporate-state-of-mind narratives. Here, the trial record—at least as summarized publicly—suggests the court concluded that the plaintiff had not established the evidentiary foundation needed to justify punitive consideration, leaving the jury to decide the merits on the underlying liability and causation questions.
Verdict and Broader Implications for Talc-Mesothelioma Litigation
On April 17, 2026, the Cook County jury returned a complete defense verdict for Merck after deliberating less than two hours. The speed and unanimity of the result, following a multi-week proceeding, indicates that jurors resolved the core dispute—specific causation—decisively in Merck’s favor. The outcome also suggests the defense’s alternative-cause presentation, supported by identified expert testimony, provided a straightforward framework for rejecting the plaintiff’s product-causation chain.
From a litigation perspective, the case stands out because it did not hinge solely on whether asbestos was present in talc or whether the plaintiff used the products, but rather on whether a competing medical explanation better accounted for the disease. While talc cases often concentrate on contamination evidence and exposure reconstruction, this verdict reflects how genetic-risk evidence and differential etiology testimony can become central to the defense in mesothelioma trials—often with input from specialists such as a pathology expert witness. The decision may encourage continued development of case-specific medical causation defenses where the record supports a plausible alternative cause.
